Evidence map›Paper›PMID 24950037›Full record

ArticleMolecular medicine (Cambridge, Mass.)2014

Decreased Langerhans cell responses to IL-36γ: altered innate immunity in patients with recurrent respiratory papillomatosis.

James DeVoti, Lynda Hatam, Alexandra Lucs, Ali Afzal, Allan Abramson, Bettie Steinberg, Vincent Bonagura

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. HomozygousProceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  13. Review
  14. Article
  15. Current and future management of recurrent respiratory papillomatosis.Laryngoscope investigative otolaryngology · 2018
    Review
  16. Article
  17. Article
  18. Article
  19. Recurrent respiratory papillomatosis: current and future perspectives.Therapeutics and clinical risk management · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

James DeVotiFeinstein Institute for Medical Research, Manhasset, New York, United States of America Division of Allergy and Immunology, Department of Pediatrics, Hofstra North Shore-LIJ School of Medicine, Great Neck, New York, United States of America.
Lynda HatamFeinstein Institute for Medical Research, Manhasset, New York, United States of America Division of Allergy and Immunology, Department of Pediatrics, Hofstra North Shore-LIJ School of Medicine, Great Neck, New York, United States of America.
Alexandra LucsFeinstein Institute for Medical Research, Manhasset, New York, United States of America Department of Otolaryngology, Hofstra North Shore-LIJ School of Medicine, Great Neck, New York, United States of America.
Ali AfzalElmezzi Graduate School of Molecular Medicine, Manhasset, New York, United States of America.
Allan AbramsonFeinstein Institute for Medical Research, Manhasset, New York, United States of America Department of Otolaryngology, Hofstra North Shore-LIJ School of Medicine, Great Neck, New York, United States of America.
Bettie SteinbergElmezzi Graduate School of Molecular Medicine, Manhasset, New York, United States of America Department of Otolaryngology, Hofstra North Shore-LIJ School of Medicine, Great Neck, New York, United States of America.
Vincent BonaguraFeinstein Institute for Medical Research, Manhasset, New York, United States of America Elmezzi Graduate School of Molecular Medicine, Manhasset, New York, United States of America Division of Allergy and Immunology, Department of Pediatrics, Hofstra North Shore-LIJ School of Medicine, Great Neck, New York, United States of America.
Feinstein Institute for Medical Research · USIcahn School of Medicine at Mount Sinai · USNorth Shore University Hospital · US

Funding

HPV-Specific, Immune Suppression in Patients with RRPR01DE017227 · NIDCR · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI BONAGURA, VINCENT ROBERT · 2006 to 2017
$4.5M
Reprogramming Host Immune Responses to Cure or Control Persistent HPV InfectionR21AI105987 · NIAID · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI BONAGURA, VINCENT ROBERT · 2013 to 2014
$589k
NIAID NIH HHS R21 AI105987NIAID NIH HHS R21AI105987NIDCR NIH HHS R01 DE017227NIDCR NIH HHS R01DE017227
6 · The paper itself

Abstract

Recurrent respiratory papillomatosis (RRP) is a rare, chronic disease caused by human papillomaviruses (HPVs) types 6 and 11 that is characterized by the polarization of adaptive immune responses that support persistent HPV infection. Respiratory papillomas express elevated mRNA levels of IL-36γ, a proinflammatory cytokine in comparison to autologous clinically normal laryngeal tissues; however there is no evidence of inflammation in these lesions. Consistent with this, respiratory papillomas do not contain TH1-like CD4(+) T-cells or cytotoxic CD8(+) T-cells, but instead contain a predominance of TH2-like and T regulatory cells (Tregs). In addition, papillomas also are infiltrated with immature Langerhans cells (iLCs). In this study, we show that papilloma cells express IL-36γ protein, and that human keratinocytes transduced with HPV11 have reduced IL-36γ secretion. We now provide the first evidence that peripheral blood-derived iLCs respond to IL-36γ by expressing inflammatory cytokines and chemokines. When stimulated with IL-36γ, iLCs from patients with RRP had lower expression levels of the TH2-like chemokine CCL-20 as compared with controls. Patients' iLCs also had decreased steady state levels of CCL-1, which is a proinflammatory chemokine. Moreover, CCL-1 levels in iLCs inversely correlated with the severity of RRP. The combined decrease of TH1- and a TH2-like chemokines by iLCs from patients could have consequences in the priming of IFN-γ expression by CD8(+) T-cells. Taken together, our results suggest that, in RRP, there is a defect in the proinflammatory innate immune responses made by iLCs in response to IL-36γ. The consequence of this defect may lead to persistent HPV infection by failing to support an effective HPV-specific, TH1-like and/or Tc1-like adaptive response, thus resulting in the predominant TH2-like and/or Treg micromilieu present in papillomas.

Indexed as

Cells, CulturedChemokine CCL1Human papillomavirus 11HumansImmunity, InnateInterleukin-1Interleukin-1betaKeratinocytesLangerhans CellsLarynxPapillomavirus InfectionsRespiratory Tract InfectionsCCL1 protein, humanChemokine CCL1IL36G protein, humanInterleukin-1Interleukin-1beta

Identifiers

PMID24950037
PMCPMC4153838
OpenAlexW2267744750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.